Ascitic fluid from advanced ovarian cancer patients compromises the activity of receptor tyrosine kinase inhibitors in 3D cell clusters of ovarian cancer cells-Reference-Cited by-同舟云学术

Ascitic fluid from advanced ovarian cancer patients compromises the activity of receptor tyrosine kinase inhibitors in 3D cell clusters of ovarian cancer cells

Published:2018-04 Issue: Volume:420 Page:168-181
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Hassan Wafaa,Chitcholtan Kenny,Sykes Peter,Garrill Ashley

Funder

Ovarian Cancer Research Foundation (OCRF), Melbourne, Australia

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference78 articles.

1. Ovarian cancer development and metastasis;Lengyel;Am. J. Pathol.,2010

2. Recurrent ovarian cancer;Tummala;Clin. Adv. Hematol. Oncol.,2005

3. Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors;Latifi;PLoS One,2012

4. Isolation and characterization of tumour cells from the ascitis of ovarian cancer patients: molecular fenotype of chemoresistant ovarian tumours;Latifi;PLoS One,2012

5. A novel perspective for an orphan problem: old and new drugs for the medical management of malignant ascites;Barni;Crit. Rev. Oncol. Hematol.,2011

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EP2/EP4 targeting prevents tumor-derived PGE2-mediated immunosuppression in cDC2s;Journal of Leukocyte Biology;2024-07-23

2. Overexpression of Fut 2, 4, and 8, and nuclear localization of Fut 4 in ovarian cancer cell lines induced by ascitic fluids from epithelial ovarian cancer patients;Cell Biology International;2024-01-23

3. Predicting Tumour Progression of ID-8 Syngeneic Mouse Ovarian Cancer with Blood Biomarkers of CA-125, IL-6 and VEGF: A Prospective Laboratory-Based Study;Clinical and Experimental Obstetrics & Gynecology;2023-10-16

4. Potential drug repurposing of ruxolitinib to inhibit the JAK/STAT pathway for the treatment of patients with epithelial ovarian cancer;Journal of Obstetrics and Gynaecology Research;2023-08-10

5. Bruceine D and afatinib combination inhibits ovarian cancer cells proliferation and migration through DNA damage repair and EGFR pathway;Journal of Investigative Medicine;2023-03-01